ICL670 in Patients With Chronic Anemia and Transfusional Hemosiderosis

2014-08-27 03:32:23 | BioPortfolio


The overall purpose of this trial is to further evaluate the efficacy and safety of deferasirox dosed initially according to the transfusional iron intake, in patients with transfusion dependant anemia related to disorders other than β-thalassemia and sickle cell disease.

It is expected that most of patients will have myelodysplastic syndromes and that patients with other type of anemia will be mainly patients with aplastic anemia, or very rare disease such as Diamond Blackfan anemia, myelofibrosis or specific enzymes deficiencies.

Study Design

Control: Uncontrolled, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment




Deferasirox (ICL670)


Novartis Investigative Site





Results (where available)

View Results


Published on BioPortfolio: 2014-08-27T03:32:23-0400

Clinical Trials [733 Associated Clinical Trials listed on BioPortfolio]

Extension Study of Iron Chelation Therapy With Deferasirox in β-thalassemia and Other Patients With Rare Chronic Anemia and Transfusional Iron Overload

A 1-year randomized Phase II core trial was conducted to investigate the efficacy of deferasirox in regularly transfused patients with β-thalassemia and other rare chronic anemia 2 years ...

Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndrome and Transfusion-dependent Iron Overload

The purpose of this study is to investigate the effects of iron chelation using deferasirox in low and INT-1 risk (referring to the international prognostic scoring system, IPSS) MDS patie...

Safety and Efficacy of ICL670 in Patients With Transfusion Dependent Iron Overload Treated in a Non Comparative Extension Study

The purpose of this study is to assess the safety and the effects on liver iron of ICL670 when given for a long treatment period in patients with transfusion dependent iron overload.

Deferasirox in Treating Patients With Very Low, Low, or Intermediate-Risk Red Blood Cell Transfusion Dependent Anemia or Myelodysplastic Syndrome

This phase II trial studies how well deferasirox works in treating patients with very low, low, or intermediate-risk anemia or myelodysplastic syndrome that depends on red blood cell trans...

A Study Assessing the Efficacy and Safety of Deferasirox in Patients With Transfusion-dependent Iron Overload

This study uses a single arm, multi-center, open-label trial design. The study will assess the efficacy and safety of 52 weeks of treatment with deferasirox (ICL670) in patients with evide...

PubMed Articles [467 Associated PubMed Articles listed on BioPortfolio]

The Clinically Used Iron Chelator Deferasirox is an Inhibitor of Epigenetic JumonjiC Domain-Containing Histone Demethylases.

Fe(II)- and 2-oxoglutarate (2OG)-dependent JumonjiC domain-containing histone demethylases (JmjC KDMs) are epigenetic eraser enzymes involved in the regulation of gene expression and are emerging drug...

Severe childhood anemia and emergency blood transfusion in Gadarif Hospital, eastern Sudan.

Anemia is a major cause of global morbidity and mortality, particularly among children. Management of anemia depends on causes and severity of anemia. However blood transfusion is a lifesaving interve...

The role of recombinant Human erythropoietin in neonatal anemia.

To estimate the blood level of Erythropoietin (EPO) in neonates with anemia of prematurity (APO) and in late hypo-regenerative anemia and to clarify role of EPO in correction of anemia and reducing th...

Prevalence of anemia in pregnant women in Styria, Austria-A retrospective analysis of mother-child examinations 2006-2014.

Many women suffer from anemia during their pregnancy. Austria, a central European country, has an instituted mandatory prenatal care system and therein two anemia screening tests (before end of week 1...

Postpartum anemia is a neglected public health issue in China: a cross-sectional study.

Anemia impairs the health and wellbeing of women and increases the risk of maternal and neonatal adverse outcomes. The objectives of this study are to determine the prevalence of postpartum anemia amo...

Medical and Biotech [MESH] Definitions

The type species of GYROVIRUS, a small, non-enveloped DNA virus originally isolated from contaminated vaccines in Japan. It causes chicken infectious anemia and may possibly play a key role in hemorrhagic anemia syndrome, anemia dermatitis, and blue wing disease.

Viral disease of horses caused by the equine infectious anemia virus (EIAV; INFECTIOUS ANEMIA VIRUS, EQUINE). It is characterized by intermittent fever, weakness, and anemia. Chronic infection consists of acute episodes with remissions.

A rare congenital hypoplastic anemia that usually presents early in infancy. The disease is characterized by a moderate to severe macrocytic anemia, occasional neutropenia or thrombocytosis, a normocellular bone marrow with erythroid hypoplasia, and an increased risk of developing leukemia. (Curr Opin Hematol 2000 Mar;7(2):85-94)

The mildest form of erythroblastosis fetalis in which anemia is the chief manifestation.

A Fanconi anemia complementation group protein that undergoes PHOSPHORYLATION by CDC2 PROTEIN KINASE during MITOSIS. It forms a complex with other FANCONI ANEMIA PROTEINS and helps protect CELLS from DNA DAMAGE by genotoxic agents.

More From BioPortfolio on "ICL670 in Patients With Chronic Anemia and Transfusional Hemosiderosis"

Quick Search

Relevant Topic

Blood is a specialized bodily fluid that delivers necessary substances to the body's cells (in animals) – such as nutrients and oxygen – and transports waste products away from those same cells.  In vertebrates, it is composed of blo...

Searches Linking to this Trial